Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | WDR5 | P61964 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25095983 | 0.94 | CYP17A1 (0.44) | CYP17A1HTTALDH1A1GAATHRB | |
| SCHEMBL29823126 | 0.87 | PKM (0.46) | CYP17A1HTTALDH1A1GAAL3MBTL1 | |
| SCHEMBL17059202 | 0.87 | PKM (0.46) | CYP17A1HTTALDH1A1GAAL3MBTL1 | |
| SCHEMBL23564871 | 0.86 | GAA (0.40) | CYP17A1HTTALDH1A1GAAMAPT | |
| SCHEMBL29760394 | 0.86 | GAA (0.40) | CYP17A1HTTALDH1A1GAAMAPT | |
| SCHEMBL28355220 | 0.85 | AAK1 (0.41) | CYP17A1HTTALDH1A1GAATHRB | |
| SCHEMBL21879364 | 0.84 | AAK1 (0.38) | CYP17A1HTTALDH1A1GAAMAPT | |
| SCHEMBL29174184 | 0.83 | MAPT (0.42) | CYP17A1HTTALDH1A1GAATHRB | |
| SCHEMBL29231709 | 0.83 | CYP17A1 (0.36) | CYP17A1HTTALDH1A1GAATHRB | |
| SCHEMBL14725520 | 0.82 | CYP17A1 (0.48) | CYP17A1LMNABRAFRXFP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117881657-A | Phenyl-sulfamoyl-benzoic acid derivatives as ERAP1 modulators | 格雷沃尔夫治疗有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20160207905-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | BLUEPRINT MEDICINES CORPORATION | 2016-07-21 | — | — | US | disclosed |
| US-20160207905-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | BLUEPRINT MEDICINES CORPORATION | 2016-07-21 | — | — | US | disclosed |
| WO-2015025197-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | JUBILANT BIOSYS LIMITED (IN) | 2015-02-26 | — | — | WO | disclosed |
| EP-0787720-B1 | PYRIDONECARBOXYLATE DERIVATIVE OR SALT THEREOF AND ANTIBACTERIAL CONTAINING THE SAME AS ACTIVE INGREDIENT | WAKUNAGA SEIYAKU KK (JP) | 2003-07-16 | — | — | EP | disclosed |
| US-5994575-A | Phenylenediamines and process for preparing the same | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 1999-11-30 | — | — | US | disclosed |
| US-5910498-A | NOVEL COMPOUNDS HAVING REDUCED CYTOTOXICITY, PHOTOTOXICITY; TREATING BACTERIAL AND VIRAL INFECTIONS | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1999-06-08 | — | — | US | disclosed |
| EP-0897909-A1 | NOVEL PHENYLENEDIAMINES AND PROCESS FOR PREPARING THE SAME | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 1999-02-24 | — | — | EP | disclosed |
| EP-0787720-A1 | NOVEL PYRIDONECARBOXYLATE DERIVATIVE OR SALT THEREOF AND ANTIBACTERIAL CONTAINING THE SAME AS ACTIVE INGREDIENT | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1997-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207905-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | TYMP, EGFR, TK1 | CYP17A1 2353/4885HTT 3318/4885ALDH1A1 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.